Axsome Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $638.5M | $385.7M | $270.6M | $0 | — | — | — |
| Cost of Revenue | — | — | — | — | $5.2M | — | — | — |
| Gross Profit | — | — | — | — | $-5.2M | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $183.3M | $187.1M | $97.9M | $57.9M | $58.1M | $70.2M | $53.6M |
| SG&A Expense | — | $570.6M | $411.4M | $323.1M | $159.3M | $66.6M | $28.9M | $13.6M |
| Operating Income | — | $-166.8M | $-280.6M | $-231.8M | $-179.8M | $-124.7M | $-99.1M | $-67.2M |
| Operating Margin | — | -26.1% | -72.7% | -85.7% | — | — | — | — |
| Interest Expense | — | $-15.9M | $-21.6M | $-20.0M | $-9.7M | — | — | — |
| Pretax Income | — | $-183.7M | $-287.1M | $-238.3M | $-187.1M | $-130.4M | — | — |
| Income Tax Expense | — | $-530.0K | $85.0K | $960.0K | $0 | $0 | $0 | $0 |
| Net Income | — | $-183.2M | $-287.2M | $-239.2M | $-187.1M | $-130.4M | $-102.9M | $-68.3M |
| Net Margin | — | -28.7% | -74.5% | -88.4% | — | — | — | — |
| EPS (Basic) | — | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | $-2.01 |
| EPS (Diluted) | — | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | $-2.01 |
| Shares Outstanding (Basic) | 51.2M | 49.7M | 47.9M | 45.4M | 40.7M | 37.6M | 37.2M | 36.9M |
| Shares Outstanding (Diluted) | 51.2M | 49.7M | 47.9M | 45.4M | 40.7M | 37.6M | 37.2M | 36.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |